Basic characterization of type 2 diabetic patients and normal subjects
| . | Type 2 diabetic patients submitted to l-arginine or placebo treatment . | Pool of type 2 diabetic patients . | Normal subjects . |
|---|---|---|---|
| Sex (M/F) | 8/4 | 14/11 | 22/18 |
| Age (years) | 57.8 ± 3.2 | 53.8 ± 2.0 | 56.3 ± 1.2 |
| Body weight (kg) | 67.0 ± 4.7 | 70.2 ± 2.3 | 70.0 ± 1.6 |
| BMI (kg/m2) | 25.3 ± 0.9 | 26.1 ± 0.7 | 25.1 ± 0.4 |
| Systolic blood pressure (mmHg) | 124 ± 3 | 129 ± 2 | 129 ± 2 |
| Diastolic blood pressure (mmHg) | 70 ± 2 | 80 ± 4* | 74 ± 2 |
| Glycated hemoglobin (%) | 5.7 ± 0.1 | 7.2 ± 0.3* | 4.9 ± 0.2† |
| Fasting plasma glucose (mmol/l) | 7.2 ± 0.2 | 7.9 ± 0.3* | 5.6 ± 0.1† |
| . | Type 2 diabetic patients submitted to l-arginine or placebo treatment . | Pool of type 2 diabetic patients . | Normal subjects . |
|---|---|---|---|
| Sex (M/F) | 8/4 | 14/11 | 22/18 |
| Age (years) | 57.8 ± 3.2 | 53.8 ± 2.0 | 56.3 ± 1.2 |
| Body weight (kg) | 67.0 ± 4.7 | 70.2 ± 2.3 | 70.0 ± 1.6 |
| BMI (kg/m2) | 25.3 ± 0.9 | 26.1 ± 0.7 | 25.1 ± 0.4 |
| Systolic blood pressure (mmHg) | 124 ± 3 | 129 ± 2 | 129 ± 2 |
| Diastolic blood pressure (mmHg) | 70 ± 2 | 80 ± 4* | 74 ± 2 |
| Glycated hemoglobin (%) | 5.7 ± 0.1 | 7.2 ± 0.3* | 4.9 ± 0.2† |
| Fasting plasma glucose (mmol/l) | 7.2 ± 0.2 | 7.9 ± 0.3* | 5.6 ± 0.1† |
Data are means ± SEM, unless otherwise indicated.
P < 0.05 vs. type 2 diabetic patients submitted to l-arginine or placebo therapy;
P < 0.05 vs. both groups of type 2 diabetic patients.